Rigel Pharmaceuticals
RIGL
124 hedge funds and large institutions have $149M invested in Rigel Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 37 reducing their positions, and 12 closing their positions.
1,036% more call options, than puts
Call options by funds: $818K | Put options by funds: $72K
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
5% more funds holding
Funds holding: 118 → 124 (+6)
0.18% more ownership
Funds ownership: 6.29% → 6.47% (+0.18%)
5% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 37
9% less capital invested
Capital invested by funds: $163M → $149M (-$14.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$20.3M |
| 2 |
Millennium Management
New York
|
+$3.26M |
| 3 |
Renaissance Technologies
New York
|
+$1.88M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.2M |
| 5 |
Two Sigma Investments
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.62M |
| 2 |
D.E. Shaw & Co
New York
|
-$5.03M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.72M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.62M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.15M |
RIGL Hedge Fund Activity: Q1 2023 in Review
124 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2023, worth a combined $149M — down 8.9% from $163M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RIGL positions and 12 closed out — a net gain of 7 holders — while 35 added to existing stakes and 37 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $20.3M. The largest seller was Fidelity Investments, cutting an estimated $9.62M.
- 124 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2023, up from 118 in Q4 2022.
- Funds reported $149M of Rigel Pharmaceuticals stock for Q1 2023, down 8.9% quarter-over-quarter.
- 19 funds opened new Rigel Pharmaceuticals positions in Q1 2023 and 12 closed out, a net change of +7 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2023 was Soleus Capital Management, an estimated $20.3M added.
- The largest Rigel Pharmaceuticals seller in Q1 2023 was Fidelity Investments, an estimated $9.62M sold.
Based on aggregated 13F filings for Q1 2023.